MedTrace Logo

Mass Balance Recovery, Absorption, Metabolism and Excretion of [14C]-BLU-5937

NCT05244759 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2022-02-17

No results posted yet for this study

Summary

This is a single-centre, open-label, non-randomised, single-period, single-dose study in healthy male subjects designed to assess the mass balance recovery, PK, metabolite profile and metabolite identification of \[14C\]-BLU-5937.

Conditions

  • Healthy

Interventions

DRUG

[14C]-BLU-5937

Each subject will receive a single oral administration of \[14C\]-BLU-5937 capsule, in the fasted state.

Sponsors & Collaborators

  • Bellus Health Inc. - a GSK company

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
30 Years
Max Age
65 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-08-25
Primary Completion
2020-09-23
Completion
2021-03-02
FDA Drug
Yes

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05244759 on ClinicalTrials.gov